GILD vs PASG · P/E 18, rev $7.80B vs $25.2M cap
Gilead Sciences Inc (GILD) versus Passage Bio Inc (PASG) — a side-by-side from cached financials, not a winner call.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US.
Passage Bio Inc (PASG) is a biotechnology company listed on US.
Latest reported GILD revenue for 2026-06-30 was $7.80B. Net income was -$10.50B. Revenue was up 12.1% from 2026-03-31 to 2026-06-30. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
PASG does not have a complete income-statement cache yet.
GILD currently screens at market cap $160.15B and trailing P/E 17.5. PASG currently screens at market cap $25.2M.
Not investment advice. Open the GILD and PASG stock pages for the full models.
Not investment advice.